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Most neurodegenerative disorders are the result of 
inflammation and neuronal cell death. Although 
many cytokines have been implied to be involved 
in the pathogenesis, recent studies have shown 
TRAIL to be responsible for neuronal apoptosis. 
TRAIL is best known for its ability to induce 
apoptosis in many cancer cells. Normally TRAIL is 
not present in the CNS. However, it is induced by 
β‐amyloid protein and upregulated on infected 
macrophages which can infiltrate the CNS. TRAIL 
is able to induce apoptosis via death receptors 
DR4 and DR5. DR5 is shown to be expressed on 
neuronal cells. The identification of an antagonistic 
peptide that specifically binds DR5 provides us 
with a useful investigative tool. Small peptides can 
bind their targets with high affinity and specificity. 
In addition, they are easily modified and further 
developed for clinical application. So the peptide 
R2C16 might even be used as a lead peptide for the 
development of therapeutic agents in 
neurodegenerative disorders. 
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The tumor necrosis factor super family (TNFSF) 
consists of a large group of cytokines that regulate 
cell survival, proliferation, differentiation and 
apoptosis. In addition, the members of the TNFSF 
share a typical jelly roll topology and they interact 
with their receptors as trimers. One of its members 
is tumor necrosis factor‐related apoptosis‐inducing 
ligand (TRAIL). TRAIL induces apoptosis via its 
death receptors, DR4 and DR5. Upon binding the 
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extracellular part of these receptors the cytoplasmic 
death domains cluster and thus the death inducing 
signaling complex (DISC) is formed. The DISC 
activates the caspase cascade which eventually 
results in apoptosis (1). TRAIL is considered to be an 
interesting therapeutic molecule, because it can 
specifically induce apoptosis in many malignant 
cells while it leaves most untransformed cells 
unharmed (2). 
Recently it has been shown that TRAIL is also 
involved in several neurodegenerative disorders as 
studies have demonstrated that neuronal loss in 
multiple sclerosis (MS), Alzheimer’s disease (AD) 
and HIV‐1 associated dementia (HAD) is related to 
TRAIL induced apoptosis. In normal, healthy CNS. 
TRAIL is not expressed, but its receptors are. 
However, under pathological conditions 
macrophages with upregulated expression of TRAIL 
have been found to infiltrate the brain (3). Another 
scenario is that TRAIL production is induced in cells 
as neurons, microglia and astrocytes by pathogens 
or immune activation (4-6). 
MS and its animal model, experimental 
autoimmune encephalitis (EAE), are characterized 
by demyelination, loss of oligodendrocytes and 
chronic inflammation of the CNS. Due to the 
inflammation macrophages expressing TRAIL might 
infiltrate the brain, leading to neuronal loss. Indeed, 
TRAIL induces apoptosis in neurons and 
additionally promotes demyelination in murine EAE 
(7). Contrarily, earlier it was demonstrated that 
inhibition of TRAIL outside the CNS worsened EAE 
in mice (8). Most recently however, TRAIL expressed 
on invaded T cells was found in close vicinity of 
dying neurons in MS patients. In EAE, this TRAIL 
was identified as the mediator of the immune attack 
against spinal cord neurons (9). 
Deposits of β‐amyloid protein in the brain are 
characteristic for AD onset (10). It was 
demonstrated that expression of both TRAIL and 
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one of its death receptors, DR5, were induced in 
neuroblastoma cells by β‐amyloid protein. These 
SH‐SY5Y cells are sensitive to TRAIL induced 
apoptosis, while treatment of the cells with 
TRAIL‐neutralizing or DR5 blocking antibody 
protected them from β‐amyloid protein neurotoxicity 
(6, 11). In addition, it was shown by immunostaining 
of cerebral cortex sections that TRAIL is expressed 
in patients with AD while it is absent in the brain of 
non‐demented patients (12). 
HAD typically occurs during the later stages of 
viral disease. Monocytes and macrophages infiltrate 
the CNS and cause neuronal damage which leads to 
disabling cognitive impairment and motor 
dysfunction (13). HIV upregulates TRAIL expression 
in macrophages of infected patients (14). Both DR4 
and DR5 are expressed on HIV‐1 encephalitic brain 
tissue. This indicates a role for the expressed TRAIL 
in HAD (3). 
Depending on the cell type TRAIL initiates its 
apoptotic signal either via DR4, via DR5 or via both 
(15, 16). For DR5 it is also known that depending on 
the reaction with different receptor agonists it can 
mediate various cell signals (17, 18). To elucidate 
these differences our laboratory has already 
designed DR4 and DR5 selective agonistic variants 
of TRAIL (19, 20, 21). For the identification of a 
selective antagonist of DR5 we decided to use a 
phage library displaying a cystein constrained 
heptamer. Earlier attempts to identify a selective 
binder to DR5 by phage display have been made by 
others (22). Here, the researchers used phage 
displayed random libraries of peptides, single chain 
variable fragments (scFv’s) and antigen binding 
fragments (Fab’s). However, their objective was to 
identify agonists of DR5 induced apoptosis and not 
antagonists of DR5. Also, there have been antibodies 
developed that bind DR5 specifically (23). Again, 
they were looking for agonists, which induce 
apoptosis and can be used in cancer treatment. 
Selection of an antagonist starts with identifying 
a binder to the elected target. A frequently used 
method is to test a library consisting of continuous 
parts of the natural ligand. Any part of the ligand 
that binds the death receptor, but does not trimerize 
nor activate the DISC would be a suitable candidate. 
However, by using a randomized library instead of 
continuous parts of the natural ligand our chances of 
success increase. In this way we can also identify the 
discontinuous amino acids that would be in a 
naturally occurring binding patch of folded protein. 
For expression and selection of our random peptide 
library we chose to use phage display, an elegant  
 
Figure 1. Schematic representation of monomeric peptide R2C16 
(top) and dimeric peptide R2C16 in both the parallel (bottom left) and 
anti‐parallel (bottom right) orientation of the two monomers. 
 
and well‐established technique linking genotype and 
phenotype. It has been demonstrated that peptides 
bind their targets with high affinity and specificity 
(24). An additional advantage of using peptides is 
that they are easily modified and further developed 
for clinical application. By simply adding a scaffold, 
such as a leucine zipper, they can be multimerized. 
Another, frequently used modification is linking of an 
antibody or specific protein to the peptides so they 
can be targeted, for instance to a specific organ (25). 
We were able to identify a cystein constrained 
heptameric peptide that is able to bind specifically 
to DR5 with high affinity: CKVILTHRC. Synthesis 
of this peptide yielded both monomeric and 
dimeric forms of the peptide. Measurements by 
MALDI‐TOF indicated the dimeric peptides 
consist of two monomers linked via disulfide 
bonds. These monomers were shown to be oriented 
both parallel and anti‐parallel (Figure 1) (26). It 
can be seen that the dimeric peptides are much 
longer compared to the monomeric peptide which 
might increase flexibility, influencing the binding 
of the peptide to the receptor. Therefore we 
decided to investigate the effects of both the 
monomeric and the dimeric peptides. Both forms 
of the peptide were able to bind to DR5 in a 
dose‐dependent manner. This was confirmed in 
ELISA and SPR studies where the binding 
towards Fc‐DR5 was investigated, and also for 
FACS studies, where the binding towards Jurkat 
cells was evaluated. The apparent Kd value of the 
dimers is more than twice as good as that of the 
monomers, 40nM compared to 272nM. In addition, 
the dimers bind the Jurkat cells much better than 
DR5 and Neurodegenerative Disorders    99 
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the monomers do, as is reflected by the higher 
fluorescent PE signal at equimolar concentrations 
(26). The observed higher avidity for the dimeric 
peptide might well be a result of the increased 
flexibility compared to the monomeric peptide, 
which would allow the dimers to adapt a more 
favourable confirmation for binding. The 
antagonizing ability of the peptides was shown in 
the colon carcinoma cell line Colo205. These cells 
are sensitive to TRAIL‐induced apoptosis and its 
death signal is transmitted via DR5 (19). 
Treatment with the peptides caused hardly any 
cell death, indicating the peptides are not 
agonistic. Preincubation with the peptides before 
TRAIL treatment showed a reduction in apoptosis 
as compared to treatment with only TRAIL. 
Pre‐incubation with the dimeric peptides was 
more efficient than with the monomers in rescuing 
the cells. These combined data demonstrate the 
peptides are able to act as antagonists and can 
inhibit TRAIL induced apoptosis, which is 
mediated via DR5 (26). 
Recognizing the importance of a better 
understanding of neurodegenerative diseases we 
think we have identified a useful research tool and 
perhaps even a candidate for drug development. The 
first step towards this would be demonstrating the 
affinity of the peptides towards brain cells 
expressing DR5. We chose the neuroblastoma cell 
line SH‐SY5Y to perform flow cytometry binding 
analyses with biotinylated monomeric and dimeric 
peptide (Figure 2). Similarly to the binding studies 
on the Jurkat cells, we found that also for the 
SH‐SY5Y cells the peptides bound in a 
dose‐dependent manner to DR5. Compared to 
control the increasing amounts of biotinylated 
monomeric and dimeric peptide showed an increase 
in fluorescence signal. The fluorescence obtained 
with the dimeric peptides is much higher than that 
with an equal molarity of monomeric peptide. Again, 
with higher concentrations of peptide the 
fluorescence signal drops back to control levels. This 
might be a result of the hydrophobic nature of the 
peptides, as we hypothesized before. While this 
hydrophobic nature complicated our studies towards 
the characteristic of the peptides, it might prove to 
be beneficial when used in the CNS, which is known 
to be lipophilic. 
Now that we know the peptides are able to bind 
DR5 on SH‐SY5Y neuroblastoma cells, we should 
investigate whether the peptides can block TRAIL 
induced apoptosis. In addition, since we have 
established the dimeric peptides to have a higher  
 
Figure 2. Dose‐response histograms of biotinylated peptide 
R2C16, monomeric (left panel) or dimeric (right panel) to 
SH‐SY5Y neuroblastoma cells. Increasing amounts of both 
monomeric (m1 = 0.29 nM, m2 = 1.14 nM, m3 = 5.71 nM) and 
dimeric (d1 = 0.14 nM, d2 = 0.57 nM, d3 = 2.86 nM) biotinylated 
peptide cause a right shift in the fluorescent PE signal compared to 
the control (C, filled grey).The curves represent the relative 
fluorescent PE signal compared to control for both monomeric (●) 
and dimeric (■) biotinylated peptide R2C16. 
 
avidity than the monomeric peptides, we could 
imagine trimers or even higher multimers to be even 
more effective. And finally, it would be interesting to 
see whether we can improve the efficiency of the 
DR5 specific peptides by linking them to a scaffold 
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